Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease. Metabolon, Inc. has announced ...

Biotie Therapies Corp. and Synosia Therapeutics Holding AG jointly announce the signing of a combination agreement through which Biotie will issue 161,448,371 shares to the shareholders and warrant ...